Effectiveness of Oseltamivir in Hospitalized Children With Laboratory-Confirmed Influenza, 2014-2023
Oseltamivir treatment was found to decrease both the likelihood of ICU admission and hospital length of stay among pediatric patients hospitalized with laboratory-confirmed influenza.
Emergence and spread of NA-I223V and NA-S247N double-mutant A(H1N1)pdm09 influenza viruses with reduced oseltamivir susceptibility in the Netherlands and beyond, 2023 to 2026
Rapid communication - findings underscore the need for ongoing genomic and phenotypic monitoring of antiviral susceptibility.
Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population
Comparing the Australian and New Zealand experiences in the evolving COVID-19 landscape highlights differences in policy and prescribing practice.
Call for tenders (HaDEA): Framework contracts to speed up the development of and access to next-generation therapeutics for infectious diseases
The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, acute respiratory distress syndrome (ARDS) or sepsis resulting from infections.
European Medicines Agency (EMA) 2025 Annual Report
The report summarises EMA's work in evaluating and monitoring human and veterinary medicines, including approval numbers for 2025.
COMBINE programme launches phase 2 of the pilot coordinated assessment procedure for combined studies
To apply to the September round, sponsors must submit their expressions of interest by 23 August 2026.
Event: 10th European Congress of Virology 2027
Organised by the European Society for Virology
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
In two open-label trials, nirmatrelvir–ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection.
